NOVARTIS PHARMACEUTICALS CORPORATION v. BECERRA et al
Case Number:
2:23-cv-14221
Court:
Nature of Suit:
Firms
Government Agencies
-
April 29, 2024
Judge Rejects 2 Challenges To Medicare Drug Price Talks
A New Jersey federal judge on Monday shot down a pair of challenges to the Medicare drug price negotiations, extending a string of court victories for the Biden administration as it defends the talks as entirely voluntary.
-
March 07, 2024
Judge Doubts Medicare Drug Pricing Amounts To 'Taking'
A New Jersey federal judge on Thursday bristled at the position by pharmaceutical companies that Medicare's drug price negotiation program is an unconstitutional "taking" that undercuts their bottom line, suggesting that the drug powerhouses needed more numbers to back their argument.
-
October 06, 2023
Mapping Big Pharma's Blitz On Medicare Drug Price Talks
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
-
September 01, 2023
Novartis Joins Legal Fray After Price Negotiation List Unveiled
Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.